230 related articles for article (PubMed ID: 17727341)
1. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors.
Wang H; Peng MS; Chen Y; Geng J; Robinson H; Houslay MD; Cai J; Ke H
Biochem J; 2007 Dec; 408(2):193-201. PubMed ID: 17727341
[TBL] [Abstract][Full Text] [Related]
2. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER
Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
Jin SL; Ding SL; Lin SC
Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
[TBL] [Abstract][Full Text] [Related]
5. Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design.
Srivani P; Usharani D; Jemmis ED; Sastry GN
Curr Pharm Des; 2008; 14(36):3854-72. PubMed ID: 19128237
[TBL] [Abstract][Full Text] [Related]
6. Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
Nankervis JL; Feil SC; Hancock NC; Zheng Z; Ng HL; Morton CJ; Holien JK; Ho PW; Frazzetto MM; Jennings IG; Manallack DT; Martin TJ; Thompson PE; Parker MW
Bioorg Med Chem Lett; 2011 Dec; 21(23):7089-93. PubMed ID: 22030030
[TBL] [Abstract][Full Text] [Related]
7. Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
Skoumbourdis AP; Leclair CA; Stefan E; Turjanski AG; Maguire W; Titus SA; Huang R; Auld DS; Inglese J; Austin CP; Michnick SW; Xia M; Thomas CJ
Bioorg Med Chem Lett; 2009 Jul; 19(13):3686-92. PubMed ID: 19464886
[TBL] [Abstract][Full Text] [Related]
8. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
Burgin AB; Magnusson OT; Singh J; Witte P; Staker BL; Bjornsson JM; Thorsteinsdottir M; Hrafnsdottir S; Hagen T; Kiselyov AS; Stewart LJ; Gurney ME
Nat Biotechnol; 2010 Jan; 28(1):63-70. PubMed ID: 20037581
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
Lee ME; Markowitz J; Lee JO; Lee H
FEBS Lett; 2002 Oct; 530(1-3):53-8. PubMed ID: 12387865
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the design of selective phosphodiesterase 4B inhibitors.
Fox D; Burgin AB; Gurney ME
Cell Signal; 2014 Mar; 26(3):657-63. PubMed ID: 24361374
[TBL] [Abstract][Full Text] [Related]
11. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
12. New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.
Guariento S; Bruno O; Fossa P; Cichero E
Mol Divers; 2016 Feb; 20(1):77-92. PubMed ID: 26290462
[TBL] [Abstract][Full Text] [Related]
13. Docking Studies of Curcumin and Analogues with Various Phosphodiesterase 4 Subtypes.
Yi YX; Gaurav A; Akowuah GA
Curr Drug Discov Technol; 2020; 17(2):248-260. PubMed ID: 30332967
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
[TBL] [Abstract][Full Text] [Related]
15. Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4.
Cedervall P; Aulabaugh A; Geoghegan KF; McLellan TJ; Pandit J
Proc Natl Acad Sci U S A; 2015 Mar; 112(12):E1414-22. PubMed ID: 25775568
[TBL] [Abstract][Full Text] [Related]
16. Discovery of triazines as selective PDE4B versus PDE4D inhibitors.
Hagen TJ; Mo X; Burgin AB; Fox D; Zhang Z; Gurney ME
Bioorg Med Chem Lett; 2014 Aug; 24(16):4031-4. PubMed ID: 24998378
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Role of Water Molecules in the Ligand Binding Domain of PDE4B and PDE4D: Virtual Screening Based Molecular Docking of Some Active Scaffolds.
Singh P; Mishra M; Agarwal S; Sau S; Iyer AK; Kashaw SK
Curr Comput Aided Drug Des; 2019; 15(4):334-366. PubMed ID: 30394213
[TBL] [Abstract][Full Text] [Related]
18. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
Keravis T; Monneaux F; Yougbaré I; Gazi L; Bourguignon JJ; Muller S; Lugnier C
PLoS One; 2012; 7(1):e28899. PubMed ID: 22247763
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
[TBL] [Abstract][Full Text] [Related]
20. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center.
Freund YR; Akama T; Alley MR; Antunes J; Dong C; Jarnagin K; Kimura R; Nieman JA; Maples KR; Plattner JJ; Rock F; Sharma R; Singh R; Sanders V; Zhou Y
FEBS Lett; 2012 Sep; 586(19):3410-4. PubMed ID: 22841723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
